샘플 요청 목록

 카트 문의
시장보고서
상품코드
1798926

세계의 이속사졸린(Isoxazoline) 시장

Isoxazoline
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 271 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

이속사졸린 세계 시장은 2030년까지 77억 달러에 달할 전망

2024년에 50억 달러로 추정되는 이속사졸린 세계 시장은 분석 기간인 2024-2030년에 CAGR 7.7%로 성장하여 2030년에는 77억 달러에 달할 것으로 예측됩니다. 이 보고서에서 분석한 부문인 플루라네르는 CAGR 5.3%를 기록하며 분석 기간 종료시에는 26억 달러에 달할 것으로 예상됩니다. 아폭솔라네르 부문의 성장률은 분석 기간 동안 CAGR 9.3%로 추정됩니다.

미국 시장은 14억 달러로 추정, 중국은 CAGR 11.6%로 성장 예측

미국의 이속사졸린 시장은 2024년에는 14억 달러에 달할 것으로 추정됩니다. 세계 2위 경제 대국인 중국은 2030년까지 16억 달러의 시장 규모에 달할 것으로 예측되며, 분석 기간인 2024-2030년 CAGR은 11.6%를 기록할 것으로 예상됩니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있고, 분석 기간 동안 CAGR은 각각 4.0%와 7.3%로 예측됩니다. 유럽에서는 독일이 CAGR 5.0%로 성장할 것으로 예측됩니다.

세계의 이속사졸린 시장 - 주요 동향과 촉진요인 정리

동물용 의약품 및 구충제 개발에서 이속사졸린이 부상하는 이유는 무엇인가?

이속사졸린은 개와 고양이의 벼룩, 진드기 등 외부 기생충의 치료와 예방을 위해 수의학에서 널리 사용되는 화합물 그룹을 말합니다. 이속사졸린 기반 분자는 곤충의 GABA- 및 글루탐산-게이트 염화물 채널의 선택적 길항제로 작용하여 포유류에 영향을 미치지 않고 기생충의 중추 신경계를 파괴합니다. 높은 특이성, 긴 작용 시간, 전신 효과로 인해 이 화합물은 국소 및 경구용 구충제로 선호되고 있습니다.

이러한 화합물은 기존 항기생충제에 영향을 미치는 내성 문제를 해결하는 데 특히 효과적입니다. 동물용 제약사들은 이속사졸린 유도체를 츄어블 정제, 스팟온 액상, 주사제 등에 지속적으로 배합하여 보호자에게 편리함을 제공하고 치료 순응도를 향상시키고 있습니다. 한 번의 투여로 여러 기생충 종을 지속적으로 구제할 수 있어 임상의와 반려동물 관리 전문가들 사이에서 그 매력이 널리 퍼지고 있습니다.

제품 개발을 촉진하는 기술 혁신과 규제 당국의 승인이란?

이속사졸린의 새로운 유도체는 활성 스펙트럼의 확대, 부작용의 최소화, 다양한 연령층과 견종에 대한 안전성 대응을 목적으로 합성되고 있습니다. 이속사졸린계 약물과 심장병 예방약, 살선충제, 기타 곤충 성장 조절제와의 병용요법은 기생충을 폭넓게 커버하기 위해 개발 중입니다. 이러한 복합제는 예방 요법을 간소화하고 시장 도입률을 향상시키는 것을 목표로 하고 있습니다.

다양한 세계 시장에서의 규제 당국의 승인으로 이속사졸린 기반 제품의 상업적 입지가 강화되고 있습니다. 엄격한 품질 및 안전성 평가를 통해 이들 화합물은 우수한 위험-편익 프로파일을 인정받았습니다. 시판 후 조사 및 현장 데이터는 장기적인 수의학적 사용의 효과와 안전성을 지속적으로 뒷받침하고 있습니다. 또한, 반려동물 케어에 대한 투자가 증가함에 따라 제약회사들이 새로운 브랜드 및 제네릭 의약품을 출시하고 있습니다.

시장 수요는 어디에서 성장하고 있으며, 주요 최종사용자는 누구인가?

특히 벼룩에 감염되기 쉬운 반려동물을 실내에서 기르는 가정이나 진드기가 창궐하는 지역에서 반려동물 건강에 대한 수요가 확대되고 있습니다. 반려동물 보호자들은 연간 투약 횟수가 적고, 안정적이고 오래 지속되는 예방약을 원하고 있습니다. 수의사와 동물병원이 주요 처방자이며, 소매 약국 및 동물병원을 통한 유통도 확대되고 있습니다.

북미와 유럽은 성숙한 시장으로 높은 반려동물 사육률, 일상적인 예방 관리 관행, 명확한 규제에 힘입어 성장하고 있습니다. 아시아태평양과 라틴아메리카는 인지도 향상과 수의학적 인프라 구축에 따라 도입이 증가하고 있습니다. 신흥 반려동물 관리 산업에서 처방전 등급의 구충제에 대한 접근성이 점차 확대되면서 수요가 더욱 증가하고 있습니다.

이속사졸린 시장 성장의 원동력은 무엇인가?

이속사졸린 시장의 성장은 반려동물 사육 수의 증가, 장기간 지속되는 효과적인 외부 기생충 구제에 대한 수요 증가, 동물용 의약품의 기술 혁신 확대 등 여러 가지 요인에 의해 이루어집니다. 약물 제형의 기술적 진보, 안전성 프로파일의 개선, 여러 기생충에 대한 광범위한 효능이 제품의 매력을 높이고 있습니다.

반려동물 클리닉, 펫케어 소매점, 온라인 동물약국 플랫폼 등 최종 사용처가 확대되면서 접근성이 향상되고 있습니다. 다양한 동물 종을 대상으로 한 조합 제품의 개발과 규제 당국의 승인으로 사용률이 더욱 높아지고 있습니다. 기생충 저항성과 반려동물 건강관리 요구가 진화하는 가운데, 이속사졸린 기반 구충제는 현대 수의학 예방의학에 있어 필수적인 존재로 남아있습니다.

부문

화합물(플루라네르, 아폭솔라네르, 사롤라네르, 로틸라네르), 반려동물 종류(고양이, 개)

조사 대상 기업 사례

  • BASF SE
  • Bayer AG
  • Boehringer Ingelheim
  • Ceva Sante Animale
  • Chanelle Pharma
  • Dechra Pharmaceuticals
  • Elanco Animal Health
  • Hitek Animal Health
  • KRKA d.d.
  • Merck Animal Health(MSD AH)
  • Norbrook Laboratories
  • Orion Corporation
  • Ourofino Saude Animal
  • PetIQ, Inc.
  • Phibro Animal Health Corporation
  • Sogeval Laboratories
  • Syngene International Ltd.
  • Vetoquinol S.A.
  • Virbac
  • Zoetis Inc.

AI 통합

Global Industry Analysts는 검증된 전문가 컨텐츠와 AI 툴을 통해 시장 정보와 경쟁 정보를 혁신하고 있습니다.

Global Industry Analysts는 LLM 및 업계 고유의 SLM을 조회하는 일반적인 규범을 따르는 대신 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양의 기업, 제품/서비스, 시장 데이터 등 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사 소재지, 제조거점, 수출입(완제품 및 OEM)을 기준으로 기업의 경쟁력 변화를 예측하고 있습니다. 이러한 복잡하고 다면적인 시장 역학은 매출원가(COGS) 증가, 수익성 하락, 공급망 재편 등 미시적, 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예상됩니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

KSM 25.09.03

Global Isoxazoline Market to Reach US$7.7 Billion by 2030

The global market for Isoxazoline estimated at US$5.0 Billion in the year 2024, is expected to reach US$7.7 Billion by 2030, growing at a CAGR of 7.7% over the analysis period 2024-2030. Fluralaner, one of the segments analyzed in the report, is expected to record a 5.3% CAGR and reach US$2.6 Billion by the end of the analysis period. Growth in the Afoxolaner segment is estimated at 9.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.4 Billion While China is Forecast to Grow at 11.6% CAGR

The Isoxazoline market in the U.S. is estimated at US$1.4 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.6 Billion by the year 2030 trailing a CAGR of 11.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.0% and 7.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.0% CAGR.

Global Isoxazoline Market - Key Trends & Drivers Summarized

Why Is Isoxazoline Gaining Ground in Animal Health and Parasiticide Development?

Isoxazoline refers to a chemical class of compounds widely used in veterinary medicine for the treatment and prevention of ectoparasites such as fleas and ticks in dogs and cats. Isoxazoline-based molecules function as selective antagonists of insect GABA- and glutamate-gated chloride channels, disrupting the central nervous system of parasites without affecting mammals. The high specificity, long duration of action, and systemic efficacy have made these compounds a preferred choice for both topical and oral parasiticide formulations.

These compounds are particularly effective in managing resistance issues that affect older antiparasitic agents. Veterinary pharmaceutical companies continue to formulate isoxazoline derivatives into chewable tablets, spot-on solutions, and injectable formats, offering convenience to pet owners and improving treatment compliance. Their utility in single-dose administration and persistent control across multiple parasite species has expanded their appeal among clinicians and pet care professionals.

What Innovations and Regulatory Approvals Are Advancing Product Development?

New derivatives of isoxazoline are being synthesized to extend spectrum of activity, minimize side effects, and address safety in different age groups and breeds. Combination therapies that pair isoxazolines with heartworm preventatives, nematocides, or other insect growth regulators are under development to provide broader parasitic coverage. These fixed-dose combinations aim to simplify preventive regimens and improve market adoption.

Regulatory approvals in various global markets have strengthened the commercial presence of isoxazoline-based products. With stringent quality and safety evaluations, these compounds have gained recognition for their favorable risk-benefit profile. Post-market surveillance and field data continue to support their efficacy and safety in long-term veterinary use. Further, rising investment in companion animal care is encouraging pharmaceutical companies to introduce new branded and generic isoxazoline formulations.

Where Is Market Demand Growing, and Who Are the Primary End-Users?

Demand is expanding in companion animal health, particularly among households with indoor pets susceptible to flea infestations and regions with endemic tick populations. Pet owners are seeking reliable, long-acting protection that requires fewer administrations per year. Veterinarians and animal hospitals are the primary prescribers, with growing distribution through retail pharmacies and veterinary clinics.

North America and Europe are mature markets, supported by high rates of pet ownership, routine preventive care practices, and regulatory clarity. Asia Pacific and Latin America are witnessing increasing adoption as awareness grows and veterinary infrastructure develops. Emerging pet care industries are gradually expanding access to prescription-grade parasiticides, further boosting demand.

What Is Driving Growth in the Isoxazoline Market?

Growth in the isoxazoline market is driven by several factors including rising pet ownership, increasing demand for long-acting and effective ectoparasite control, and expanding veterinary pharmaceutical innovation. Technological advances in drug formulation, improved safety profiles, and broader efficacy against multiple parasites are enhancing product attractiveness.

End-use expansion in companion animal clinics, pet care retail, and online veterinary pharmacy platforms is improving accessibility. Combination product development and regulatory approvals for diverse animal species are further strengthening usage. As parasite resistance and pet healthcare needs evolve, isoxazoline-based parasiticides are positioned to remain essential in modern veterinary preventive medicine.

SCOPE OF STUDY:

The report analyzes the Isoxazoline market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Chemical Compound (Fluralaner, Afoxolaner, Sarolaner, Lotilaner); Pet Type (Cat, Dog)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

  • BASF SE
  • Bayer AG
  • Boehringer Ingelheim
  • Ceva Sante Animale
  • Chanelle Pharma
  • Dechra Pharmaceuticals
  • Elanco Animal Health
  • Hitek Animal Health
  • KRKA d.d.
  • Merck Animal Health (MSD AH)
  • Norbrook Laboratories
  • Orion Corporation
  • Ourofino Saude Animal
  • PetIQ, Inc.
  • Phibro Animal Health Corporation
  • Sogeval Laboratories
  • Syngene International Ltd.
  • Vetoquinol S.A.
  • Virbac
  • Zoetis Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Isoxazoline - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Pet Ownership and Veterinary Care Spending Drive Demand for Isoxazoline-Based Ectoparasiticides
    • Expansion of Companion Animal Flea and Tick Treatment Segments Strengthens Role of Isoxazoline in Oral and Topical Formulations
    • OEM Innovation in Broad-Spectrum Molecules Enhances Efficacy Against Resistant Flea and Mite Populations
    • Growth in Preference for Long-Acting, Monthly Dosing Schedules Throws Spotlight on Systemic Isoxazoline Compounds
    • Increasing Regulatory Approvals for Next-Generation Isoxazolines Supports Rapid Geographic Market Entry
    • OEM Development of Palatable, Species-Specific Delivery Formats Enhances Compliance in Dogs and Cats
    • Rising Incidence of Vector-Borne Diseases in Animals Promotes Preventive Use of Isoxazoline Products
    • OEM Focus on Combination Therapies With Endoparasitic Coverage Expands Utility of Isoxazoline Molecules
    • Surge in E-Commerce Veterinary Drug Sales Supports Access to Isoxazoline-Based Products Without In-Clinic Visits
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Isoxazoline Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Isoxazoline by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Isoxazoline by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Isoxazoline by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Fluralaner by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Fluralaner by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Fluralaner by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Afoxolaner by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Afoxolaner by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Afoxolaner by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Sarolaner by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Sarolaner by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Sarolaner by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Lotilaner by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Lotilaner by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Lotilaner by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Cat by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Cat by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Cat by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Dog by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Dog by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 22: World 16-Year Perspective for Dog by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Isoxazoline Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 23: USA Recent Past, Current & Future Analysis for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 25: USA 16-Year Perspective for Isoxazoline by Chemical Compound - Percentage Breakdown of Value Sales for Fluralaner, Afoxolaner, Sarolaner and Lotilaner for the Years 2014, 2025 & 2030
    • TABLE 26: USA Recent Past, Current & Future Analysis for Isoxazoline by Pet Type - Cat and Dog - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Isoxazoline by Pet Type - Cat and Dog Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 28: USA 16-Year Perspective for Isoxazoline by Pet Type - Percentage Breakdown of Value Sales for Cat and Dog for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 29: Canada Recent Past, Current & Future Analysis for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 31: Canada 16-Year Perspective for Isoxazoline by Chemical Compound - Percentage Breakdown of Value Sales for Fluralaner, Afoxolaner, Sarolaner and Lotilaner for the Years 2014, 2025 & 2030
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Isoxazoline by Pet Type - Cat and Dog - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Canada Historic Review for Isoxazoline by Pet Type - Cat and Dog Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 34: Canada 16-Year Perspective for Isoxazoline by Pet Type - Percentage Breakdown of Value Sales for Cat and Dog for the Years 2014, 2025 & 2030
  • JAPAN
    • Isoxazoline Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 35: Japan Recent Past, Current & Future Analysis for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Japan Historic Review for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 37: Japan 16-Year Perspective for Isoxazoline by Chemical Compound - Percentage Breakdown of Value Sales for Fluralaner, Afoxolaner, Sarolaner and Lotilaner for the Years 2014, 2025 & 2030
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Isoxazoline by Pet Type - Cat and Dog - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Japan Historic Review for Isoxazoline by Pet Type - Cat and Dog Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 40: Japan 16-Year Perspective for Isoxazoline by Pet Type - Percentage Breakdown of Value Sales for Cat and Dog for the Years 2014, 2025 & 2030
  • CHINA
    • Isoxazoline Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 41: China Recent Past, Current & Future Analysis for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: China Historic Review for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 43: China 16-Year Perspective for Isoxazoline by Chemical Compound - Percentage Breakdown of Value Sales for Fluralaner, Afoxolaner, Sarolaner and Lotilaner for the Years 2014, 2025 & 2030
    • TABLE 44: China Recent Past, Current & Future Analysis for Isoxazoline by Pet Type - Cat and Dog - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: China Historic Review for Isoxazoline by Pet Type - Cat and Dog Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 46: China 16-Year Perspective for Isoxazoline by Pet Type - Percentage Breakdown of Value Sales for Cat and Dog for the Years 2014, 2025 & 2030
  • EUROPE
    • Isoxazoline Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Isoxazoline by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Isoxazoline by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 49: Europe 16-Year Perspective for Isoxazoline by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 52: Europe 16-Year Perspective for Isoxazoline by Chemical Compound - Percentage Breakdown of Value Sales for Fluralaner, Afoxolaner, Sarolaner and Lotilaner for the Years 2014, 2025 & 2030
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Isoxazoline by Pet Type - Cat and Dog - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Isoxazoline by Pet Type - Cat and Dog Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 55: Europe 16-Year Perspective for Isoxazoline by Pet Type - Percentage Breakdown of Value Sales for Cat and Dog for the Years 2014, 2025 & 2030
  • FRANCE
    • Isoxazoline Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 56: France Recent Past, Current & Future Analysis for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: France Historic Review for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 58: France 16-Year Perspective for Isoxazoline by Chemical Compound - Percentage Breakdown of Value Sales for Fluralaner, Afoxolaner, Sarolaner and Lotilaner for the Years 2014, 2025 & 2030
    • TABLE 59: France Recent Past, Current & Future Analysis for Isoxazoline by Pet Type - Cat and Dog - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: France Historic Review for Isoxazoline by Pet Type - Cat and Dog Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 61: France 16-Year Perspective for Isoxazoline by Pet Type - Percentage Breakdown of Value Sales for Cat and Dog for the Years 2014, 2025 & 2030
  • GERMANY
    • Isoxazoline Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Germany Historic Review for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 64: Germany 16-Year Perspective for Isoxazoline by Chemical Compound - Percentage Breakdown of Value Sales for Fluralaner, Afoxolaner, Sarolaner and Lotilaner for the Years 2014, 2025 & 2030
    • TABLE 65: Germany Recent Past, Current & Future Analysis for Isoxazoline by Pet Type - Cat and Dog - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Germany Historic Review for Isoxazoline by Pet Type - Cat and Dog Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 67: Germany 16-Year Perspective for Isoxazoline by Pet Type - Percentage Breakdown of Value Sales for Cat and Dog for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Italy Historic Review for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 70: Italy 16-Year Perspective for Isoxazoline by Chemical Compound - Percentage Breakdown of Value Sales for Fluralaner, Afoxolaner, Sarolaner and Lotilaner for the Years 2014, 2025 & 2030
    • TABLE 71: Italy Recent Past, Current & Future Analysis for Isoxazoline by Pet Type - Cat and Dog - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Italy Historic Review for Isoxazoline by Pet Type - Cat and Dog Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 73: Italy 16-Year Perspective for Isoxazoline by Pet Type - Percentage Breakdown of Value Sales for Cat and Dog for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Isoxazoline Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 74: UK Recent Past, Current & Future Analysis for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: UK Historic Review for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 76: UK 16-Year Perspective for Isoxazoline by Chemical Compound - Percentage Breakdown of Value Sales for Fluralaner, Afoxolaner, Sarolaner and Lotilaner for the Years 2014, 2025 & 2030
    • TABLE 77: UK Recent Past, Current & Future Analysis for Isoxazoline by Pet Type - Cat and Dog - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: UK Historic Review for Isoxazoline by Pet Type - Cat and Dog Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 79: UK 16-Year Perspective for Isoxazoline by Pet Type - Percentage Breakdown of Value Sales for Cat and Dog for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 80: Spain Recent Past, Current & Future Analysis for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Spain Historic Review for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 82: Spain 16-Year Perspective for Isoxazoline by Chemical Compound - Percentage Breakdown of Value Sales for Fluralaner, Afoxolaner, Sarolaner and Lotilaner for the Years 2014, 2025 & 2030
    • TABLE 83: Spain Recent Past, Current & Future Analysis for Isoxazoline by Pet Type - Cat and Dog - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Spain Historic Review for Isoxazoline by Pet Type - Cat and Dog Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 85: Spain 16-Year Perspective for Isoxazoline by Pet Type - Percentage Breakdown of Value Sales for Cat and Dog for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 86: Russia Recent Past, Current & Future Analysis for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Russia Historic Review for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 88: Russia 16-Year Perspective for Isoxazoline by Chemical Compound - Percentage Breakdown of Value Sales for Fluralaner, Afoxolaner, Sarolaner and Lotilaner for the Years 2014, 2025 & 2030
    • TABLE 89: Russia Recent Past, Current & Future Analysis for Isoxazoline by Pet Type - Cat and Dog - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Russia Historic Review for Isoxazoline by Pet Type - Cat and Dog Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 91: Russia 16-Year Perspective for Isoxazoline by Pet Type - Percentage Breakdown of Value Sales for Cat and Dog for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Rest of Europe Historic Review for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 94: Rest of Europe 16-Year Perspective for Isoxazoline by Chemical Compound - Percentage Breakdown of Value Sales for Fluralaner, Afoxolaner, Sarolaner and Lotilaner for the Years 2014, 2025 & 2030
    • TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Isoxazoline by Pet Type - Cat and Dog - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Rest of Europe Historic Review for Isoxazoline by Pet Type - Cat and Dog Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 97: Rest of Europe 16-Year Perspective for Isoxazoline by Pet Type - Percentage Breakdown of Value Sales for Cat and Dog for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Isoxazoline Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Isoxazoline by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for Isoxazoline by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 100: Asia-Pacific 16-Year Perspective for Isoxazoline by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 103: Asia-Pacific 16-Year Perspective for Isoxazoline by Chemical Compound - Percentage Breakdown of Value Sales for Fluralaner, Afoxolaner, Sarolaner and Lotilaner for the Years 2014, 2025 & 2030
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Isoxazoline by Pet Type - Cat and Dog - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Isoxazoline by Pet Type - Cat and Dog Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 106: Asia-Pacific 16-Year Perspective for Isoxazoline by Pet Type - Percentage Breakdown of Value Sales for Cat and Dog for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Isoxazoline Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 107: Australia Recent Past, Current & Future Analysis for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Australia Historic Review for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 109: Australia 16-Year Perspective for Isoxazoline by Chemical Compound - Percentage Breakdown of Value Sales for Fluralaner, Afoxolaner, Sarolaner and Lotilaner for the Years 2014, 2025 & 2030
    • TABLE 110: Australia Recent Past, Current & Future Analysis for Isoxazoline by Pet Type - Cat and Dog - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Australia Historic Review for Isoxazoline by Pet Type - Cat and Dog Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 112: Australia 16-Year Perspective for Isoxazoline by Pet Type - Percentage Breakdown of Value Sales for Cat and Dog for the Years 2014, 2025 & 2030
  • INDIA
    • Isoxazoline Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 113: India Recent Past, Current & Future Analysis for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: India Historic Review for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 115: India 16-Year Perspective for Isoxazoline by Chemical Compound - Percentage Breakdown of Value Sales for Fluralaner, Afoxolaner, Sarolaner and Lotilaner for the Years 2014, 2025 & 2030
    • TABLE 116: India Recent Past, Current & Future Analysis for Isoxazoline by Pet Type - Cat and Dog - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: India Historic Review for Isoxazoline by Pet Type - Cat and Dog Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 118: India 16-Year Perspective for Isoxazoline by Pet Type - Percentage Breakdown of Value Sales for Cat and Dog for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 119: South Korea Recent Past, Current & Future Analysis for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: South Korea Historic Review for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 121: South Korea 16-Year Perspective for Isoxazoline by Chemical Compound - Percentage Breakdown of Value Sales for Fluralaner, Afoxolaner, Sarolaner and Lotilaner for the Years 2014, 2025 & 2030
    • TABLE 122: South Korea Recent Past, Current & Future Analysis for Isoxazoline by Pet Type - Cat and Dog - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: South Korea Historic Review for Isoxazoline by Pet Type - Cat and Dog Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 124: South Korea 16-Year Perspective for Isoxazoline by Pet Type - Percentage Breakdown of Value Sales for Cat and Dog for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 125: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Rest of Asia-Pacific Historic Review for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 127: Rest of Asia-Pacific 16-Year Perspective for Isoxazoline by Chemical Compound - Percentage Breakdown of Value Sales for Fluralaner, Afoxolaner, Sarolaner and Lotilaner for the Years 2014, 2025 & 2030
    • TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Isoxazoline by Pet Type - Cat and Dog - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Rest of Asia-Pacific Historic Review for Isoxazoline by Pet Type - Cat and Dog Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 130: Rest of Asia-Pacific 16-Year Perspective for Isoxazoline by Pet Type - Percentage Breakdown of Value Sales for Cat and Dog for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Isoxazoline Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 131: Latin America Recent Past, Current & Future Analysis for Isoxazoline by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 132: Latin America Historic Review for Isoxazoline by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 133: Latin America 16-Year Perspective for Isoxazoline by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 136: Latin America 16-Year Perspective for Isoxazoline by Chemical Compound - Percentage Breakdown of Value Sales for Fluralaner, Afoxolaner, Sarolaner and Lotilaner for the Years 2014, 2025 & 2030
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Isoxazoline by Pet Type - Cat and Dog - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Isoxazoline by Pet Type - Cat and Dog Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 139: Latin America 16-Year Perspective for Isoxazoline by Pet Type - Percentage Breakdown of Value Sales for Cat and Dog for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 140: Argentina Recent Past, Current & Future Analysis for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Argentina Historic Review for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 142: Argentina 16-Year Perspective for Isoxazoline by Chemical Compound - Percentage Breakdown of Value Sales for Fluralaner, Afoxolaner, Sarolaner and Lotilaner for the Years 2014, 2025 & 2030
    • TABLE 143: Argentina Recent Past, Current & Future Analysis for Isoxazoline by Pet Type - Cat and Dog - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Argentina Historic Review for Isoxazoline by Pet Type - Cat and Dog Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 145: Argentina 16-Year Perspective for Isoxazoline by Pet Type - Percentage Breakdown of Value Sales for Cat and Dog for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 146: Brazil Recent Past, Current & Future Analysis for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Brazil Historic Review for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 148: Brazil 16-Year Perspective for Isoxazoline by Chemical Compound - Percentage Breakdown of Value Sales for Fluralaner, Afoxolaner, Sarolaner and Lotilaner for the Years 2014, 2025 & 2030
    • TABLE 149: Brazil Recent Past, Current & Future Analysis for Isoxazoline by Pet Type - Cat and Dog - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Brazil Historic Review for Isoxazoline by Pet Type - Cat and Dog Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 151: Brazil 16-Year Perspective for Isoxazoline by Pet Type - Percentage Breakdown of Value Sales for Cat and Dog for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 152: Mexico Recent Past, Current & Future Analysis for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Mexico Historic Review for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 154: Mexico 16-Year Perspective for Isoxazoline by Chemical Compound - Percentage Breakdown of Value Sales for Fluralaner, Afoxolaner, Sarolaner and Lotilaner for the Years 2014, 2025 & 2030
    • TABLE 155: Mexico Recent Past, Current & Future Analysis for Isoxazoline by Pet Type - Cat and Dog - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Mexico Historic Review for Isoxazoline by Pet Type - Cat and Dog Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 157: Mexico 16-Year Perspective for Isoxazoline by Pet Type - Percentage Breakdown of Value Sales for Cat and Dog for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 158: Rest of Latin America Recent Past, Current & Future Analysis for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Rest of Latin America Historic Review for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 160: Rest of Latin America 16-Year Perspective for Isoxazoline by Chemical Compound - Percentage Breakdown of Value Sales for Fluralaner, Afoxolaner, Sarolaner and Lotilaner for the Years 2014, 2025 & 2030
    • TABLE 161: Rest of Latin America Recent Past, Current & Future Analysis for Isoxazoline by Pet Type - Cat and Dog - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Rest of Latin America Historic Review for Isoxazoline by Pet Type - Cat and Dog Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 163: Rest of Latin America 16-Year Perspective for Isoxazoline by Pet Type - Percentage Breakdown of Value Sales for Cat and Dog for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Isoxazoline Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 164: Middle East Recent Past, Current & Future Analysis for Isoxazoline by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 165: Middle East Historic Review for Isoxazoline by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 166: Middle East 16-Year Perspective for Isoxazoline by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 169: Middle East 16-Year Perspective for Isoxazoline by Chemical Compound - Percentage Breakdown of Value Sales for Fluralaner, Afoxolaner, Sarolaner and Lotilaner for the Years 2014, 2025 & 2030
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Isoxazoline by Pet Type - Cat and Dog - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Isoxazoline by Pet Type - Cat and Dog Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 172: Middle East 16-Year Perspective for Isoxazoline by Pet Type - Percentage Breakdown of Value Sales for Cat and Dog for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 173: Iran Recent Past, Current & Future Analysis for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Iran Historic Review for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 175: Iran 16-Year Perspective for Isoxazoline by Chemical Compound - Percentage Breakdown of Value Sales for Fluralaner, Afoxolaner, Sarolaner and Lotilaner for the Years 2014, 2025 & 2030
    • TABLE 176: Iran Recent Past, Current & Future Analysis for Isoxazoline by Pet Type - Cat and Dog - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Iran Historic Review for Isoxazoline by Pet Type - Cat and Dog Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 178: Iran 16-Year Perspective for Isoxazoline by Pet Type - Percentage Breakdown of Value Sales for Cat and Dog for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 179: Israel Recent Past, Current & Future Analysis for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Israel Historic Review for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 181: Israel 16-Year Perspective for Isoxazoline by Chemical Compound - Percentage Breakdown of Value Sales for Fluralaner, Afoxolaner, Sarolaner and Lotilaner for the Years 2014, 2025 & 2030
    • TABLE 182: Israel Recent Past, Current & Future Analysis for Isoxazoline by Pet Type - Cat and Dog - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Israel Historic Review for Isoxazoline by Pet Type - Cat and Dog Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 184: Israel 16-Year Perspective for Isoxazoline by Pet Type - Percentage Breakdown of Value Sales for Cat and Dog for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 185: Saudi Arabia Recent Past, Current & Future Analysis for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Saudi Arabia Historic Review for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 187: Saudi Arabia 16-Year Perspective for Isoxazoline by Chemical Compound - Percentage Breakdown of Value Sales for Fluralaner, Afoxolaner, Sarolaner and Lotilaner for the Years 2014, 2025 & 2030
    • TABLE 188: Saudi Arabia Recent Past, Current & Future Analysis for Isoxazoline by Pet Type - Cat and Dog - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Saudi Arabia Historic Review for Isoxazoline by Pet Type - Cat and Dog Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 190: Saudi Arabia 16-Year Perspective for Isoxazoline by Pet Type - Percentage Breakdown of Value Sales for Cat and Dog for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 191: UAE Recent Past, Current & Future Analysis for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: UAE Historic Review for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 193: UAE 16-Year Perspective for Isoxazoline by Chemical Compound - Percentage Breakdown of Value Sales for Fluralaner, Afoxolaner, Sarolaner and Lotilaner for the Years 2014, 2025 & 2030
    • TABLE 194: UAE Recent Past, Current & Future Analysis for Isoxazoline by Pet Type - Cat and Dog - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: UAE Historic Review for Isoxazoline by Pet Type - Cat and Dog Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 196: UAE 16-Year Perspective for Isoxazoline by Pet Type - Percentage Breakdown of Value Sales for Cat and Dog for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 197: Rest of Middle East Recent Past, Current & Future Analysis for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Rest of Middle East Historic Review for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 199: Rest of Middle East 16-Year Perspective for Isoxazoline by Chemical Compound - Percentage Breakdown of Value Sales for Fluralaner, Afoxolaner, Sarolaner and Lotilaner for the Years 2014, 2025 & 2030
    • TABLE 200: Rest of Middle East Recent Past, Current & Future Analysis for Isoxazoline by Pet Type - Cat and Dog - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Rest of Middle East Historic Review for Isoxazoline by Pet Type - Cat and Dog Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 202: Rest of Middle East 16-Year Perspective for Isoxazoline by Pet Type - Percentage Breakdown of Value Sales for Cat and Dog for the Years 2014, 2025 & 2030
  • AFRICA
    • Isoxazoline Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 203: Africa Recent Past, Current & Future Analysis for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Africa Historic Review for Isoxazoline by Chemical Compound - Fluralaner, Afoxolaner, Sarolaner and Lotilaner Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 205: Africa 16-Year Perspective for Isoxazoline by Chemical Compound - Percentage Breakdown of Value Sales for Fluralaner, Afoxolaner, Sarolaner and Lotilaner for the Years 2014, 2025 & 2030
    • TABLE 206: Africa Recent Past, Current & Future Analysis for Isoxazoline by Pet Type - Cat and Dog - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Africa Historic Review for Isoxazoline by Pet Type - Cat and Dog Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 208: Africa 16-Year Perspective for Isoxazoline by Pet Type - Percentage Breakdown of Value Sales for Cat and Dog for the Years 2014, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제